Strategies to Reduce Iron Deficiency
Public ClinicalTrials.gov record NCT02245321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The prevalence of iron deficiency in blood donors has been demonstrated to be a direct consequence of repeat blood donations. Given the adverse effects of iron deficiency, it is priority to implement programs to remediate iron deficiency issues associated with blood donations. To explore this issue, the study's aims to: 1. Determine whether regular blood donors provided with accurate information about their iron status and written recommended courses of action will take steps to prevent/mitigate iron deficiency on their own without being given iron supplements by the blood center; and 2. Determine if two different amounts of iron provided by the blood center will prevent/mitigate iron deficiency in regular blood donors. To conduct this randomized, placebo controlled study, participant donors will be assigned to one of two arms and followed for a 24 month period. Each subject will provide additional blood samples of 7 ml and 4.5 ml at each study visit for the purpose of tracking hemoglobin (Hgb), ferritin, soluble transferrin receptor (sTfR), and hematology laboratory results. Under the two study arms, subjects are to be randomized into one of the following five blinded categories: * Receive a thank you letter after each blood donation. * Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation. * Receive pills to take daily that contain no iron (a placebo or inert pill). * Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron). * Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
Study identification
- NCT ID
- NCT02245321
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 702 participants
Conditions and interventions
Conditions
Interventions
- Ferrous gluconate- 19 mg Dietary Supplement
- Ferrous gluconate- 38 mg Dietary Supplement
- Letter Group- Information Provided Other
- Letter - No Information Provided Other
- Placebo Dietary Supplement
Dietary Supplement · Other
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2011
- Primary completion
- Apr 30, 2014
- Completion
- May 31, 2014
- Last update posted
- Dec 5, 2023
2011 – 2014
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| American Red Cross, Connecticut Region | Farmington | Connecticut | 06032 | — |
| Westat | Rockville | Maryland | 20850 | — |
| The Institute for Transfusion Medicince | Pittsburgh | Pennsylvania | 15220 | — |
| BloodCenter of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Iron Deficiency trials
Other public records listing Iron Deficiency. Sorted by last update posted; newest first. Not a recommendation.
- NCT04945707: Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) Active, not recruiting
- NCT07686692: IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency Not yet recruiting
- NCT07546591: A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females Recruiting
- NCT05340465: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants Recruiting
- NCT07217873: IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study Recruiting
- NCT06798584: How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function? Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02245321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2023 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02245321 live on ClinicalTrials.gov.